1. One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease
- Author
-
Mar Riveiro-Barciela, Angela Carvalho-Gomes, Ana Barreira, Helena Hernandez-Évole, Francisco Rodriguez-Frias, Rafael Esteban, María García-Eliz, Luisa Roade, Antonio Madejón, Sabela Lens, Sara Sopena, Sergio Rodriguez-Tajes, Ana Isabel Gil-García, Adriana Palom, Javier García-Samaniego, Marina Berenguer-Hayme, and Maria Buti
- Subjects
Male ,Hepatitis B virus ,HBsAg ,medicine.medical_specialty ,Cirrhosis ,Hepatitis D, Chronic ,viruses ,Hbv markers ,Disease ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Chronic hepatitis ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Natural course ,Hepatitis B Surface Antigens ,Hepatology ,business.industry ,virus diseases ,Middle Aged ,biochemical phenomena, metabolism, and nutrition ,Serum samples ,medicine.disease ,Hepatitis D ,DNA, Viral ,RNA ,Quantitative hbsag ,030211 gastroenterology & hepatology ,Hepatitis Delta Virus ,business - Abstract
BACKGROUND Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). AIMS To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these changes with other HBV markers. METHODS A total of 323 consecutive serum samples from 56 CHD patients (detectable HDV-RNA) followed for >3 years were retested for HDV-RNA levels by a sensitive technique using the first WHO international HDV-RNA standard. Quantitative HBsAg, HBV-DNA, and HBV-RNA were also determined. RESULTS Most participants were male, middle-aged, white European, and HBeAg-negative (82%). Almost half had liver cirrhosis and 64% were receiving nucleos(t)ide analogues. At inclusion, median-HDV-RNA was 5.3 (4.2-6.5) log10 IU/mL, HBsAg 4.0 (3.5-4.3) log10 IU/mL, and HBV-DNA 1.6 (1.0-2.6) log10 IU/mL; ALT values were normal in 13 (23%). During a mean follow-up of 5.6 (3-16) years, 14 (25%) showed ≥2log10 HDV-RNA decline, including 11 (20%) who spontaneously achieved undetectable HDV-RNA. Four patients (7%) lost HBsAg, with undetectable HDV-RNA. The remaining 42 (75%) had persistently detectable HDV-RNA. During follow-up, patients with a ≥2log10 HDV-RNA decline showed a greater HBsAg drop (-0.7 ± 1.1 vs -0.09 ± 0.9 log IU/mL; P = 0.039) than those with a
- Published
- 2021